Cholinesterases
Cholinesterases inactivate the neurotransmitter acetylcholine by catalyzing its hydrolysis to choline and acetic acid. Acetylcholinesterase (AChE) is found in erythroid cells and at neuronal synapses, whilst butyrylcholinesterase is mostly expressed in the liver.
Cholinesterase Inhibitors |
|
|---|---|
| Cat. No. | Product Name / Activity |
| 0388 | Ambenonium dichloride |
| Cholinesterase inhibitor | |
| 4385 | Donepezil hydrochloride |
| Potent AChE inhibitor | |
| 0686 | Galanthamine hydrobromide |
| Cholinesterase inhibitor | |
| 4086 | PE 154 |
| Fluorescent, potent AChE and BChE inhibitor | |
| 0622 | Physostigmine hemisulfate |
| Cholinesterase inhibitor | |
| 4440 | Rivastigmine tartrate |
| Dual AChE and BChE inhibitor | |
| 0965 | Tacrine hydrochloride |
| Cholinesterase inhibitor | |
Cholinesterases inactivate the neurotransmitter acetylcholine by catalyzing its hydrolysis to choline and acetic acid. Acetylcholinesterase (AChE) is found in erythroid cells and at neuronal synapses, whilst butyrylcholinesterase is mostly expressed in the liver. The high enzymatic rate of AChE means that it effectively terminates signal transmission at cholinergic synpases.
AChE is the target of organophosphate nerve agents such as sarin and VX. Clinically, AChE inhibitors have found a number of uses, with physostigmine used to treat glaucoma. AChE inhibitors are also used in the management of mild to moderate Alzheimer's disease.
External sources of pharmacological information for Cholinesterases :
Literature for Cholinesterases
Tocris offers the following scientific literature for Cholinesterases to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Neurodegeneration Product Guide
A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:
- Alzheimer's disease
- Parkinson's disease
- Huntington's disease
Alzheimer's Poster
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Our Neurodegeneration guide highlights over 275 products for neurodegeneration research.
Request copyRequest PDFWritten by Alan Palmer
Our Alzheimer's disease poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease.
Request copyDownload PDF